May 6, 2015 (TORONTO) – Following the Annual General Meeting of BIOTECanada, the BIOTECanada Board of Directors is pleased to announce the election of three Directors to the Board. The new Directors include:

Sanj Singh, President & CEO, Ade Therapeutics

Shermaine Tilley, Managing Partner, CSI Life Sciences Fund

Eric Tse, General Manager, Shire Pharma Canada ULC

“The new Board members represent the Canadian biotech industry’s ecosystem where companies, research institutions, and investors all work together to advance innovative solutions to address Canadian and global challenges,” commented David Main, Chairman BIOTECanada.

“Joining the BIOTECanada Board comes at a time when CTI Life Sciences recently closed a new $134 Million venture capital fund,” commented Shermaine Tilley, Managing Partner CTI Life Sciences. “There is a significant amount of investment capital looking at Canadian biotech companies. Having worked with many BIOTECanada member companies over the past number of years, I look forward to continue to offer operational and venture capital experience to create shareholder value.”

“I have worked closely with BIOTECanada over the years with the Emerging Company Advisory Board,” commented Sanj Singh, President and CEO AdeTherapeutics Inc. “As founder of an emerging biotech company in Canada I look forward to supporting the interests of pre-commercial member companies to attract world class teams, build strategic partnerships and raise capital.”

“Joining the BIOTECanada Board represents an important opportunity for Shire to increase its involvement within the biotech ecosystem at a time where the presence of Shire continues to grow in Canada,” commented Eric Tse, General Manager at Shire Pharma Canada ULC. “This is an important time for life sciences in Canada.”

“I thank outgoing Directors for their time and commitment to the Association. The Board truly appreciate Tony Cruz (Transition Therapeutics), John Helou (Pfizer Canada) and Hervé Lilliu (UCB) for their contribution to the industry throughout their terms,” commented Andrew Casey, President and CEO BIOTECanada. “Welcome to the new Directors. I look forward to working with the entire Board in promoting key public policy initiatives which will drive the Canadian biotech industry.”